A rationale for the treatment of metastatic neuroblastoma.
In developing a chemotherapeutic program for children with disseminated neuroblastoma, we established three human neuroblastoma lines in cell culture to study the effects of dibutyryl cyclic AMP, papaverine, 5-trifluoromethyl-2'-deoxyuridine, and cyclophosphamide on cell growth, biochemical behavior, and morphology. Based upon our studies, a clinical treatment program was designed. We have treated 15 patients with disseminated neuroblastoma and have established the optimum dose range and sequence of these drugs. Early results were promising; plans for continuation of clinical and experimental studies were discussed.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003994:Bucladesine / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D005467:Floxuridine / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D009362:Neoplasm Metastasis; D009447:Neuroblastoma / Q000188:drug therapy*; D010208:Papaverine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D005467:Floxuridine; D014750:Vincristine; D003994:Bucladesine; D003520:Cyclophosphamide; D010208:Papaverine